These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 18568074)

  • 1. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to ErbB-targeted cancer therapeutics.
    Wang Q; Greene MI
    J Clin Invest; 2008 Jul; 118(7):2389-92. PubMed ID: 18568082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
    Choi YJ; Park GM; Rho JK; Kim SY; So GS; Kim HR; Choi CM; Lee JC
    PLoS One; 2013; 8(12):e81393. PubMed ID: 24339922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
    Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
    Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
    Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
    BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
    J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
    Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
    PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
    J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Peled N; Wynes MW; Ikeda N; Ohira T; Yoshida K; Qian J; Ilouze M; Brenner R; Kato Y; Mascaux C; Hirsch FR
    Cell Oncol (Dordr); 2013 Jul; 36(4):277-88. PubMed ID: 23619944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
    Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells.
    Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY
    Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
    Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
    J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
    Huang MH; Lee JH; Chang YJ; Tsai HH; Lin YL; Lin AM; Yang JC
    Mol Oncol; 2013 Feb; 7(1):112-20. PubMed ID: 23102728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.